A Prospective, Single-Arm, Phase Ib/II Clinical Study of the EZH2 Inhibitor Zeprumetostat in Combination with Glofitamab plus GemOx for the Treatment of Relapsed/Refractory DLBCL (ChiCTR) - Oct 16, 2026 - P4 | N=52 | Not yet recruiting | Sponsor: Jiangsu Province Hospital (The First Affiliated Hospital with Nanjing Medical University); Jiangsu Province Hospital (The First Affiliated Hospital wi
New P4 trial • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin's Lymphoma • Oncology
|